This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-06 and is reviewed periodically as new material appears.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The longest Romanian word is pneumonoultramicroscopicsilicovolcaniconioză, with 44 letters, (meaning "pneumonultramicroscopicsilicovolcanoconiosis") but the longest one admitted by the Dicționarul explicativ al limbii române ("Explanatory Dictionary of the Romanian Language", DEX) is electroglotospectrografie, with 25 letters.
== See also == In vitro fertilisation (IVF) Animal testing Ex vivo In situ In utero In vivo In silico In papyro In natura Animal in vitro cellular and developmental biology Plant in vitro cellular and developmental biology In vitro toxicology In vitro to in vivo extrapolation Slice preparation
IDMS appears to give lower values than older methods when the serum creatinine values are relatively low, for example 0.7 mg/dL. The IDMS method would result in comparative overestimation of the corresponding calculated GFR in some patients with normal renal function. A few medicines are dosed even in normal renal function using that derived value of GFR. The dose, unless further modified, could then be higher than desired, potentially causing increased drug-related toxicity. To counter the effect of changing to IDMS, new FDA guidelines have suggested limiting doses of carboplatin, a chemotherapy drug, to specified maxima.
Weizmann's political efforts picked up speed, and on 10 December 1914 he met with Herbert Samuel, a British Cabinet member and a secular Jew who had studied Zionism; Samuel believed Weizmann's demands were too modest. Two days later, Weizmann met Balfour again, for the first time since their initial meeting in 1905; Balfour had been out of government ever since his electoral defeat in 1906, but remained a senior member of the Conservative Party in their role as Official Opposition. A month later, Samuel circulated a memorandum entitled The Future of Palestine to his Cabinet colleagues. The memorandum stated: "I am assured that the solution of the problem of Palestine which would be much the most welcome to the leaders and supporters of the Zionist movement throughout the world would be the annexation of the country to the British Empire". Samuel discussed a copy of his memorandum with Nathan Rothschild in February 1915, a month before the latter's death. It was the first time in an official record that enlisting the support of Jews as a war measure had been proposed. Many further discussions followed, including the initial meetings in 1915–16 between Lloyd George, who had been appointed Minister of Munitions in May 1915, and Weizmann, who was appointed as a scientific advisor to the ministry in September 1915. Seventeen years later, in his War Memoirs, Lloyd George described these meetings as being the "fount and origin" of the declaration; historians have rejected this claim.
The reaction involves adsorption of protons onto S8 clusters, followed by disproportionation into the reaction products. The second, fourth and sixth ionization energies of sulfur are 2252 kJ/mol, 4556 kJ/mol and 8495.8 kJ/mol, respectively. The composition of reaction products of sulfur with oxidants (and its oxidation state) depends on whether releasing of reaction energy overcomes these thresholds. Applying catalysts and/or supply of external energy may vary sulfur's oxidation state and the composition of reaction products. While reaction between sulfur and oxygen under normal conditions gives sulfur dioxide (oxidation state +4), formation of sulfur trioxide (oxidation state +6) requires a temperature of 400–600 °C (750–1,100 °F) and presence of a catalyst. In reactions with elements of lesser electronegativity, it reacts as an oxidant and forms sulfides, where it has oxidation state −2. Sulfur reacts with nearly all other elements except noble gases, even with the notoriously unreactive metal iridium (yielding iridium disulfide). Some of those reactions require elevated temperatures.
Sources: en.wikipedia.org
Acrosin is a digestive enzyme that acts as a protease. In humans, acrosin is encoded by the ACR gene. Acrosin is released from the acrosome of spermatozoa as a consequence of the acrosome reaction. It aids in the penetration of the Zona Pellucida.
Therefore, while the electronic placement of hydrogen in group 1 predominates, some rarer arrangements show either hydrogen in group 17, duplicate hydrogen in both groups 1 and 17, or float it separately from all groups. This last option has nonetheless been criticized by the chemist and philosopher of science Eric Scerri on the grounds that it appears to imply that hydrogen is above the periodic law altogether, unlike all the other elements. Helium is the only element that routinely occupies a position in the periodic table that is not consistent with its electronic structure. It has two electrons in its outermost shell, whereas the other noble gases have eight; and it is an s-block element, whereas all other noble gases are p-block elements. However it is unreactive at standard conditions, and has a full outer shell: these properties are like the noble gases in group 18, but not at all like the reactive alkaline earth metals of group 2. For these reasons helium is nearly universally placed in group 18 which its properties best match; a proposal to move helium to group 2 was rejected by IUPAC in 1988 for these reasons. Nonetheless, helium is still occasionally placed in group 2 today, and some of its physical and chemical properties are closer to the group 2 elements and support the electronic placement. Solid helium crystallises in a hexagonal close-packed structure, which matches beryllium and magnesium in group 2, but not the other noble gases in group 18.
Commercially pure zinc is known as Special High Grade, often abbreviated SHG, and is 99.995% pure. Worldwide, 95% of new zinc is mined from sulfidic ore deposits, in which sphalerite (ZnS) is nearly always mixed with the sulfides of copper, lead and iron. Zinc mines are scattered throughout the world, with the main areas being China, Australia, and Peru. China produced 38% of the global zinc output in 2014. Zinc metal is produced using extractive metallurgy. The ore is finely ground, then put through froth flotation to separate minerals from gangue (on the property of hydrophobicity), to get a zinc sulfide ore concentrate consisting of about 50% zinc, 32% sulfur, 13% iron, and 5% SiO2. Roasting converts the zinc sulfide concentrate to zinc oxide:
== Tissue distribution == Studies have detected FFAR2 protein and/or its messenger RNA (an indicator of FFAR2 protein expression) in the following cell types, cell lines, and tissues: 1) human and rodent enteroendocrine K cells, i.e., cells located in the epithelium of the small intestine; 2) human and rodent enteroendocrine L cells, i.e., cells located in the epithelium of the small intestine and colon; 3) human and rodent fat tissue and/or cultured fat cells; 4) cells in human and rodent pancreatic islets (these islets contain the beta cells and alpha cells that synthesize and secrete insulin and glucagon, respectively, into the blood); 5) cells in and/or derived from cells in the human or mouse spleen, lymph nodes, bone marrow, and blood (e.g., monocytes, lymphocytes, and neutrophils); 6) mouse and, based on indirect studies, human dendritic cells; 7) cells in or derived from cells in human and/or rodent kidneys, hearts, brains (e.g., hypothalamus), fetal membranes, and placentas; 8) cells in the taste buds' lingual papillae of human tongues; 9) mouse renal arteries, aortas, and iliac arteries; 10) various human cell lines including SW480, SW620, HT-29, and T84 colon cancer cells, NCI-H716 colon cancer cells that have a lymphoblast morphology, Caco-2 colorectal cancer cells, Hutu-80 duodenal cancer cells, SW872 liposarcoma cells, MDA-MB-231, MDA-MB-436, and MCF7 breast cancer cells, Huh7 and JHH-4 liver cancer cells, THP-1 acute myeloid leukemia cells, U937 acute promyelocytic leukemia cells, and K562 myelogenous leukemia cells; and 11) the various mouse and rat cell lines discussed below. FFAR2 is also expressed in a wide range of tissues in other animals such as cows, pigs, sheep, cats, and dogs.
Diacetyl production is favored in fermentations that run warm with temperatures between 18 and 25 °C (64 and 77 °F). It also tends to be produced at higher levels in wines with lower pH levels (under 3.5), though at levels below 3.2, most strains of LAB desirable for MLF tend to be inhibited. "Wild" (as in uninoculated) malolactic ferments have the potential to produce more diacetyl than inoculated ferments due to the lower initial populations during the lag phase with inoculated ferments usually having an initial inoculum of 106 CFU/mL. Late MLF inoculations, after alcoholic fermentation, also tend to produce higher levels of diacetyl. Chardonnay producers desiring to make the high-diacetyl "buttery style" will often do late or "wild" inoculation in the barrel after primary fermentation, allowing the wine to spend several weeks or even months sur lie in reductive conditions that promote diacetyl production. Some sources point out that diacetyl is actually decreased by sur lie, due to surviving yeast metabolizing diacetyl, and therefore malolactic fermentation is best performed apart from lees. With wines that have excessive levels of diacetyl, some winemakers use sulfur dioxide to bind with the compound and reduce the perception of diacetyl by 30 to 60%. This binding is a reversible process and after only a few weeks aging in the bottle or tank, the high levels of diacetyl return.
Sources: en.wikipedia.org
Under the terms of his 2011 employment agreement, McCord received $529,994 in direct compensation as well as a 50-cent commission on every bottle of Protandim sold. McCord served as LifeVantage's Chief Scientific Officer from June 2011 until September 2012, and then became a member of its science advisory board. LifeVantage announced McCord's retirement in June 2013. Under the terms of the separation agreement, McCord was to receive a payment of $1.7 million from the company. In January 2014, McCord was replaced by Shawn Talbott (developer of CortiSlim), who served as the company's chief science officer until being relieved of his duties in June 2015 and replaced in August 2015 by Natalie Chevreau, who was hired as the company's senior vice president of research and development and is credited with the invention of the company's TruScience skin care product.
=== Russia === The use of ractopamine in Russia is prohibited. On 6 June 2011, the Russian Ministry of Agriculture notified key meat import/exporters in Russia of a future prohibition of ractopamine in meat imported to Russia. On 7 December 2012, the prohibition went into force, and pork and beef export to Russia required submission of compliance certificates confirming absence of ractopamine in exported meat.
== History == Lactobacillus delbrueckii subsp. bulgaricus was first identified in 1905 by Stamen Grigorov, who named it Bacillus bulgaricus. Ilya Metchnikoff, a professor at the Pasteur Institute in Paris, researched the relationship between the longevity of Bulgarians and their consumption of yogurt. He had the idea that aging is caused by putrefactive activity, or proteolysis, by microbes that produce toxic substances in the intestine. Proteolytic bacteria such as clostridia, which are part of the normal intestinal flora, produce toxic substances including phenols, ammonia and indols by digestion of proteins. These compounds are responsible for what Metchnikoff called intestinal auto-intoxication, which, according to him, was the cause of the physical changes associated with old age. It was already known at that time that fermentation with lactic acid bacteria inhibits the deterioration of milk because of its low pH. Metchnikoff's research also noted that rural populations in Southeastern Europe and the Russian steppes daily consume milk fermented with lactic acid bacteria and live relatively longer than other populations. Based on these data Metchnikoff proposed that consumption of fermented milk seeds the intestine with harmless lactic acid bacteria increasing intestinal acidity and suppressing the growth of proteolytic bacteria. His results were questioned after a 1920 study showed that the bacterium could not survive in the human intestines, but the idea nevertheless started the research into actually useful probiotics.
10 mm (0.4 in) – it has well-defined gill arches and has a thin ventral finfold 21 mm (0.8 in) – dorsal and pelvic fin buds appear 33 mm (1.3 in) – embryo has protruding eyes and well-developed gill filaments 43 mm (1.7 in) – it has lost its translucency and develops slits in the egg case, allowing fluid exchange from surrounding seawater and the interior 58 mm (2.3 in) – the finfold starts to decay 66 mm (2.6 in) – the finfold and gill filaments are reduced or absent 74 mm (2.9 in) – external appearance is complete but yolk sac is still being absorbed 100–110 mm (3.9–4.3 in) – hatching
=== Proteasomal deubiquitinases === Ubiquitin chains conjugated to a protein targeted for proteasomal degradation are normally removed by any one of the three proteasome-associated deubiquitylating enzymes (DUBs), which are Rpn11, Ubp6/USP14 and UCH37. Rpn11 is the essential DUB responsible for the en block removal of the ubiquitin signal from the substrate, while Ubp6/USP14 and UCH37 have been proposed to edit the ubiquitin code. Ubp6 knockouts in Saccharomyces cerevisiae are viable, and there is no homolog of UCH37 in budding yeast, though they exist in Schizosaccharomyces pombe and higher eukaryotes. This process recycles ubiquitin and is essential to maintain the ubiquitin reservoir in cells.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.